PartnershipsExpediteBio and AVS Bio Partner to Enable Fully Integrated Developability Driven Antibody Development and Manufacturing
PartnershipsNIZO food research and Winclove Probiotics join forces in strategic partnership built on interdependency and microbial innovation
IndustryGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
IndustryGlobally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment
IndustryAgomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
PartnershipsExpediteBio and AVS Bio Partner to Enable Fully Integrated Developability Driven Antibody Development and Manufacturing
PartnershipsNIZO food research and Winclove Probiotics join forces in strategic partnership built on interdependency and microbial innovation
IndustryGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
IndustryGlobally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment
PartnershipsExpediteBio and AVS Bio Partner to Enable Fully Integrated Developability Driven Antibody Development and Manufacturing
PartnershipsNIZO food research and Winclove Probiotics join forces in strategic partnership built on interdependency and microbial innovation
IndustryGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
IndustryGlobally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment